DDAVP infusion can modify VASP phosphorylation in human platelets

Hézard, Nathalie; Jallu, Vincent; Garnotel, Roselyne; Kaplan, C.; Nguyên, Philippe

doi:10.1111/j.1538-7836.2004.00690.x

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other data are not consistent, describing enhanced in vitro sensitivity to aggregating agents [45,46] or expression of CD62 [47] or formation of microparticles and generation of procoagulant activity [48] following DDAVP stimulation. Consistent with previous data suggesting that the final effect of DDAVP on platelets involves the facilitation of Gp IIb-IIIa-ligand interactions [21,45], the recently reported phosphorylation of the cytoskeleton focal adhesion protein VASP, which is closely related to the Gp IIb-IIIa complex and modulates the binding of platelets to fibrinogen and VWF, could represent a molecular mechanism and a marker of platelet effects of DDAVP [49]. Advances in cellular mechanisms of the haemostatic effects of desmopressin have been recently reviewed [50].…”

Section: Ddavp and Improvement Of Platelet Function: How Does It Work?supporting

confidence: 90%

Desmopressin in inherited disorders of platelet function

Coppola

Minno

2007

Haemophilia

View full text Add to dashboard Cite

Following the first clinical use in haemophilia and von Willebrand disease in 1977, the synthetic analogue of vasopressin 1-deamino-8-D-arginine vasopressin (DDAVP, desmopressin) was successfully employed for the management of a series of bleeding disorders, including congenital and acquired defects of platelet function. In this setting, few haemostatic approaches are available and, in particular for severe bleeding and major invasive procedures, the transfusion of platelet concentrates is the first-choice treatment. Therefore, DDAVP was (and remains) an attractive therapeutic alternative, being well tolerated, cost-saving, administrable at home (by the intranasal or subcutaneous concentrated formulations) and, in particular, enabling the avoidance of blood product exposition and the related risks (allergic reactions, transfusion transmitted infections). Despite three decades of clinical use, cellular mechanisms of haemostatic effects of DDAVP in platelet defects remain poorly known and the excellent results reported in some case series have not been strengthened by rigorous clinical trials, hampered by the rarity and the heterogeneity of these disorders. However, clinical experience more than evidence-based medicine reserved an established place to DDAVP in the management of inherited platelet disorders. This review will focus the available clinical data and the open issues of DDAVP in this setting.

show abstract

Section: Ddavp and Improvement Of Platelet Function: How Does It Work?supporting

confidence: 90%

Desmopressin in inherited disorders of platelet function

Coppola

Minno

2007

Haemophilia

View full text Add to dashboard Cite

show abstract

“…This effect appears to be mediated by direct interaction of VWF with GPIIb-IIIa 13,34,35 and not with GPIb-a. 34,39,40 The most interesting observation of our study is the ability of in vivo DDAVP infusion to enhance the generation of procoagulant COAT platelets (Figure 4). COAT platelets are a subpopulation of platelets generated by simultaneous activation with collagen and thrombin.…”

Section: Discussionmentioning

confidence: 85%

The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects

Colucci

Stutz

Rochat

et al. 2014

Blood

View full text Add to dashboard Cite

Key Points• DDAVP is the drug of choice for mild hemophilia A and von Willebrand disease and (by unclear mechanisms) for platelet function disorders.• In vivo DDAVP selectively and markedly enhances the ability to form procoagulant platelets by enhancing intracellular Na 1 and Ca 21 fluxes.is clinically efficacious in patients with mild platelet function disorders but it is not known which mechanisms mediate this effect. Our aim was to evaluate the impact of in vivo DDAVP administration in these patients. We assessed von Willebrand factor (VWF), factor VIII, platelet activation and aggregation, platelet-dependent thrombin generation, and platelet intracellular Na 1 /Ca 21 fluxes, before and 2 and 4 hours after DDAVP (0.3 mg/kg). We found (1) no significant changes for P-selectin expression, PAC-1 binding, d-granule content and secretion, and platelet-aggregation; (2) significant decreases of secretion of a-granules and GPIIb-IIIa activation induced by adenosine 59-diphosphate, convulxin, and thrombin; (3) significant increases of procoagulant platelets induced by convulxin/thrombin and platelet-dependent thrombin generation; and (4) significant increases of intracellular Na 1 /Ca 21 concentrations. We show that in vivo DDAVP selectively and markedly enhances the ability to form procoagulant platelets and increases platelet-dependent thrombin generation by enhancing Na

show abstract

“…It has been suggested that the final effect of DDAVP on platelets involves the facilitation of glycoprotein (Gp) IIbIIIa ligand interactions through the cytoskeleton focal adhesion protein VASP. This molecular mechanism modulates platelets binding to fibrinogen and vWF [33].…”

Section: Discussionmentioning

confidence: 99%

Splenectomy for Visceral Leishmaniasis Out of an Endemic Region: A Case Report and Literature Review

et al. 2022

View full text Add to dashboard Cite

Visceral leishmaniasis (also known as kala-azar) is characterized by fever, weight loss, swelling of the spleen and liver, and pancytopenia. If it is not treated, the fatality rate in developing countries can be as high as 100% within 2 years. In a high risk situation for perioperative bleeding due to severe thrombocytopenia/coagulopathy, we present a rare challenge for urgent splenectomy in a patient with previously undiagnosed visceral leishmaniasis. A histologic examination of the spleen revealed a visceral leishmaniasis, and the patient was successfully treated with amphotericin B.

show abstract

DDAVP infusion can modify VASP phosphorylation in human platelets

Cited by 5 publications

References 6 publications

Desmopressin in inherited disorders of platelet function

Desmopressin in inherited disorders of platelet function

The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects

Splenectomy for Visceral Leishmaniasis Out of an Endemic Region: A Case Report and Literature Review

Contact Info

Product

Resources

About